Displaying drugs 8401 - 8425 of 12915 in total
Befovacimab
Investigational
Maropitant
Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats.
Vet approved
Matched Iupac: … (2S,3S)-N-[(5-tert-butyl-2-methoxyphenyl)methyl]-2-(diphenylmethyl)-1-azabicyclo[2.2.2]octan-3-amine …
Matched Description: … Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis …
Matched Description: … Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis …
Tripotassium (1R)-4-biphenyl-4-yl-1-phosphonatobutane-1-sulfonate
Experimental
Matched Name: … Tripotassium (1R)-4-biphenyl-4-yl-1-phosphonatobutane-1-sulfonate …
Matched Iupac: … potassium (1R)-4-{[1,1'-biphenyl]-4-yl}-1-[bis(potassiooxy)phosphoryl]butane-1-sulfonate …
Matched Iupac: … potassium (1R)-4-{[1,1'-biphenyl]-4-yl}-1-[bis(potassiooxy)phosphoryl]butane-1-sulfonate …
Ezabenlimab
Investigational
Matched Synonyms: … Anti-pd-1 monoclonal antibody bi 754091 ... Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human monoclonal bi754091 …
MVA-BN-brachyury-TRICOM vaccine
MVA-BN-brachyury-TRICOM vaccine is an investigational cancer vaccine. It is composed of recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human transcription factor and tumour-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1...
Investigational
Matched Description: … ICAM-1 and LFA-3. ... MVA-BN), encoding the human transcription factor and tumour-associated antigen (TAA) brachyury, and a ... molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, …
Pexacerfont
Pexacerfont has been investigated for the treatment of Alcoholism, Anxiety Disorder, Alcohol Dependence, and Alcohol-Related Disorders.
Investigational
Matched Iupac: … N-[(2R)-butan-2-yl]-8-(6-methoxy-2-methylpyridin-3-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
7-(alpha-D-Glucopyranosyloxy)-4-methyl-2H-1-benzopyran-2-one
Experimental
Matched Synonyms: … 4-Methylumbelliferyl a-D-glucopyranoside ... 7-(α-D-glucopyranosyloxy)-4-methyl-2H-1-benzopyran-2-one ... 7-(alpha-D-Glucopyranosyloxy)-4-methyl-2H-1-benzopyran-2-one …
Matched Name: … 7-(alpha-D-Glucopyranosyloxy)-4-methyl-2H-1-benzopyran-2-one …
Matched Name: … 7-(alpha-D-Glucopyranosyloxy)-4-methyl-2H-1-benzopyran-2-one …
Litifilimab
Litifilimab is under investigation in clinical trial NCT05531565 (A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) And/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory And/or Intolerant to Antimalarial Therapy).
Investigational
Matched Synonyms: … Immunoglobulin g1, anti-(human blood dendritic cell antigen 2) (human-mus musculus monoclonal biib059 .gamma.1- …
Matched Description: … Litifilimab is under investigation in clinical trial NCT05531565 (A Study to Assess the Efficacy and …
Matched Description: … Litifilimab is under investigation in clinical trial NCT05531565 (A Study to Assess the Efficacy and …
CRA_10991
Experimental
Matched Iupac: … 2-{5-[amino(iminiumyl)methyl]-6-chloro-1H-indol-2-yl}-6-(cyclopentyloxy)benzen-1-olate …
CRA_10762
Experimental
Matched Iupac: … 6-chloro-2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1H-1,3-benzodiazole-5-carboximidamide …
RB106
Experimental
Matched Iupac: … (2S,5R)-5-phenyl-1-{2-[(2S)-3-phenyl-2-sulfanylpropanamido]acetyl}pyrrolidine-2-carboxylic acid …
CRA_10972
Experimental
Matched Iupac: … 6-chloro-2-[2-hydroxy-3-(2-methylpropoxy)phenyl]-1H-1,3-benzodiazole-5-carboximidamide …
CRA_11092
Experimental
Matched Iupac: … 6-fluoro-2-(2-hydroxy-3-{[(1S,2S)-2-methylcyclohexyl]oxy}phenyl)-1H-1,3-benzodiazole-5-carboximidamide …
CRA_10656
Experimental
Matched Iupac: … 2-{5-[amino(iminiumyl)methyl]-1H-1,3-benzodiazol-2-yl}-6-(2-methylpropoxy)benzen-1-olate …
TG-100801
TG100801 is a topically applied kinase inhibitor in macular degeneration patients. It is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological hallmarks of AMD and other back of the eye...
Investigational
Matched Iupac: … 4-chloro-3-[5-methyl-3-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2,4-benzotriazin-7-yl]phenyl benzoate …
Matched Description: … TG100801 is a topically applied kinase inhibitor in macular degeneration patients. …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Description: … TG100801 is a topically applied kinase inhibitor in macular degeneration patients. …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
CP-122721
CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.
Investigational
Matched Iupac: … (2S,3S)-N-{[2-methoxy-5-(trifluoromethoxy)phenyl]methyl}-2-phenylpiperidin-3-amine …
Matched Description: … CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Description: … CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
CPG 10101
CPG 10101 is a synthetic oligodeoxynucleotide (ODN) in clinical trials. It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV.
Investigational
Matched Description: … CPG 10101 is a synthetic oligodeoxynucleotide (ODN) in clinical trials. ... It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could …
BIO-11006
BIO-11006 is under investigation in clinical trial NCT03202394 (Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS).
Investigational
Matched Iupac: … phenylpropanamido]-3-hydroxypropanamido]hexanamido]-3-hydroxybutanamido]propanamido]propanamido]hexanoic ... 6-amino-2-[(2S)-2-[(2S)-2-[(2S)-4-carbamoyl-2-[(2S)-2-(2-acetamidoacetamido)propanamido]butanamido]-3- …
KB109
KB109 is a prebiotic to feed healthy bacteria for them to to outcompete multi-drug resistance organisms.
Investigational
Matched Description: … KB109 is a prebiotic to feed healthy bacteria for them to to outcompete multi-drug resistance organisms …
P-BCMA-101
P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.
Investigational
MBL-HCV1
MBL-HCV1 is a monoclonal antibody developed to prevent the recurrence of hepatitis C virus (HCV) in patients receiving a liver transplant.
Investigational
Matched Description: … receiving a liver transplant. ... MBL-HCV1 is a monoclonal antibody developed to prevent the recurrence of hepatitis C virus (HCV) in patients …
Displaying drugs 8401 - 8425 of 12915 in total